Bastion Therapeutics
Creating a future where inflammatory disorders are curable
Creating a future where inflammatory disorders are curable
Bastion Therapeutics is a preclinical stage biotech startup founded in 2018 and headquartered in the United Kingdom. The company's mission is to develop novel Treg cell therapies to address the unmet clinical need for inflammatory disorders. They leverage their proprietary GRIT™ platform technology to engineer Tregs and aim to overcome challenges associated with previous generations of Treg cell therapies. The vision of Bastion Therapeutics is to provide life-changing therapies that are efficacious, durable, and safe to patients suffering from inflammatory disorders. The company has recently secured a $840.00K Venture Round investment on 12 September 2023. The investors in this round include NG Bio, Wren Capital LLP, Deep Science Ventures, and Pioneer Group. With its promising approach and the support of notable investors, Bastion Therapeutics is poised to make significant strides in the field of biotechnology and potentially revolutionize the treatment of inflammatory disorders.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $840.00K | 4 |
|
12 Sep 2023 |
No recent news or press coverage available for Bastion Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.